In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer
February 10 2023 - 7:17AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death, and immuno-oncology targeted novel
biologics, today announced initial results evaluating the synergy
of HSB-1216 with immune checkpoint inhibitors in KRAS G12C-mutated
non-small cell lung cancer (NSCLC) cells, Calu-1, with
Pembrolizumab, an anti-PD-1 antibody. The study demonstrated
significantly greater tumor inhibition of Calu-1 cells, when grown
with human PBMCs (SEB-activated) and treated with HSB-1216 and
Pembrolizumab.
“We are greatly encouraged by the initial results showing
crosstalk and synergy between an established and validated
immuno-oncology pathway, anti-PD-1, and Ferroptosis, a new emerging
iron-dependent cell death pathway and mechanism of action for
HSB-1216,” said Randy Milby, Hillstream’s Chief Executive
Officer.
Lung cancer remains one of the leading causes of cancer-related
deaths worldwide with NSCLC accounting for approximately 80–85% of
all cases. Despite significant progress and the development of
anti-PD-1/PDL-1 therapeutics, the estimated 5-years overall
survival (OS) remains low. anti-PD-1/PDL-1 therapeutics have
substantially improved overall survival with an acceptable safety
profile in NSCLC patients, however, not all patients respond.
Several combination strategies are under evaluation, including
evaluation of chemotherapy, targeted therapies and other modalities
in combination with immunotherapy.
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death, and immuno-oncology targeted novel
biologics. The Company’s most advanced candidate, HSB-1216,
expected to enter clinical trials in 2023, targets ferroptosis, an
emerging new anti-cancer mechanism resulting in iron mediated cell
death (IMCD) of drug resistant cancers. The Company’s emerging
immuno-oncology pipeline is led by the HSB-1940 Quatrabody™, an
anti-PD-1 novel biologic coated onto Quatramers, expected to enter
the clinic in 2024.
Hillstream’s Quatramer™ proprietary tumor targeting platform
extends duration of action and minimizes off-target toxicity for
biologics, mRNA, peptides, small molecules and other modalities in
the tumor microenvironment. Quatrabody conjugates novel biologics
developed against undruggable epitopes of validated immuno-oncology
targets, including PD-1, HER2, PDL-1, TROP2 and now MUC1-C, with
greater binding affinity than approved therapies. For more
information, please visit: www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2021 and our periodic reports filed
with the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Hillstream does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.Investor Relations
Contact:Email: investorrelations@hillstreambio.comwww.hillstreambio.com
Source: Hillstream BioPharma Inc.
A graph accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/39734abf-bc37-43f3-91f8-ffb8063b817b
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Sep 2023 to Sep 2024